TGI
RLAY icon

TRV GP III’s Relay Therapeutics RLAY Stock Holding History

TRV GP III’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,551,115
Closed -$439M – 8
2020
Q4 		$439M Hold
10,551,115
– – 37.66% 1
2020
Q3 		$449M Buy
+10,551,115
New +$402M 37.75% 1

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

TRV GP III's RLAY Position: Q1 2021 in Review

TRV GP III sold out of Relay Therapeutics (RLAY) in Q1 2021, closing a stake of 10,551,115 shares — an estimated $439M sold.

TRV GP III first reported a position in RLAY in Q3 2020 and held it in 2 quarters. The position peaked at $449M in Q3 2020. 137 funds tracked by Wall St. Rank hold RLAY as of Q1 2021.

  • TRV GP III reported no remaining Relay Therapeutics position as of Q1 2021 after selling out during the quarter.
  • TRV GP III sold 10,551,115 Relay Therapeutics shares in Q1 2021, an estimated $439M.
  • TRV GP III first reported a position in Relay Therapeutics in Q3 2020 and held it in 2 quarters.
  • TRV GP III's Relay Therapeutics position peaked at $449M in Q3 2020.
  • 137 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2021.

Based on TRV GP III's 13F filing for Q1 2021, filed 12 May 2021.